Regulus Therapeutics Falls 12% Following HCV Clinical Study Results
February 09, 2015 at 13:19 PM EST
Shares of Regulus Therapeutics Inc (NASDAQ: RGLS) fell sharply at Monday’s open following the release of the company’s ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.